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Measurement of 18F-FDG PET tumor heterogeneity improves
early assessment of response to bevacizumab compared with
the standard size and uptake metrics in a colorectal
cancer model
Usman Bashira,*, Amanda Weeksb,*, Jayant S. Godab, Muhammad Siddiqueb,
Vicky Goha,d and Gary J. Cooka,c
Purpose Treatment of metastatic colorectal cancer
frequently includes antiangiogenic agents such as
bevacizumab. Size measurements are inadequate to
assess treatment response to these agents, and newer
response assessment criteria are needed. We aimed to
evaluate 18F-FDG PET-derived texture parameters in a
preclinical colorectal cancer model as alternative metrics of
response to treatment with bevacizumab.
Materials and methods Fourteen CD1 athymic mice
injected in the flank with 5×106 LS174T cells (human
colorectal carcinoma) were either untreated controls (n= 7)
or bevacizumab treated (n= 7). After 2 weeks, mice
underwent 18F-FDG PET/CT. Calliper-measured tumor
growth (Δvol) and final tumor volume (Volcal), 18F-FDG PET
metabolically active volume (Volmet), mean metabolism
(Metmean), and maximum metabolism (Metmax) were
measured. Twenty-four texture features were compared
between treated and untreated mice. Immunohistochemical
mean tumor vascular density was estimated by anti-CD-34
staining after tumor resection.
Results Treated mice had significantly lower tumor
vascular density (P= 0.032), confirming the antiangiogenic
therapeutic effect of bevacizumab. None of the conventional
measures were different between the two groups: Δvol
(P= 0.9), Volcal (P= 0.7), Volmet (P= 0.28), Metmax (P= 0.7), or
Metmean (P= 0.32). One texture parameter, GLSZM-SZV
(visually indicating that the 18F-FDG PET images of treated
mice comprise uniformly sized clusters of different activity)
had significantly different means between the two groups
of mice (P= 0.001).
Conclusion 18F-FDG PET derived texture parameters,
particularly GLSZM-SZV, may be valid biomarkers of tumor
response to treatment with bevacizumab, before change in
volume. Nucl Med Commun 00:000–000 Copyright © 2019
Wolters Kluwer Health, Inc. All rights reserved.
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Introduction
Early detection of response to treatment is an increasingly
important goal in personalized medicine. Bevacizumab is a
monoclonal antibody to the vascular endothelial growth
factor-A (VEGF-A) receptor [1]. It selectively targets
immature new vessels within tumors and has a vascular
maturation effect, whereby highly permeable, immature
vessels are replaced by more mature vessels [1–3]. These
changes manifest as decreasing vascular permeability in
tumor regions rich in VEGF-A expression [4,5]. Because of
the reported survival benefits of bevacizumab, several
regimens combining bevacizumab with cytoreductive
agents are being used in the treatment of colorectal cancer
[1]. Like most anticancer therapeutic regimens, early
response assessment is critical to identify nonresponders
and switch regimens.
Because bevacizumab is not cytoreductive, responding
tumors may not decrease in size early during treatment
making serial size measurement on morphologic imaging
unreliable for response assessment [4]. Dynamic computed
tomography (CT) and MRI have shown promise in directly
measuring the antiangiogenic effect of bevacizumab treat-
ment [2,4]. However, the relatively complex nature of
some of these CT and MRI protocols limits their use
to institutions that have the technical expertise [6].
Furthermore, as most of these protocols utilize contrast
media, patients with poor renal function cannot benefit
from them. 18F-FDG PET imaging has also been used to
determine metabolic changes in tumors undergoing bev-
acizumab treatment [2,7,8]. Conventionally, metrics of
tumor metabolism have been based on whole-tumor
assessment, for example, mean standardized uptake value
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(SUVmean) and metabolically active tumor volume (Volmet),
or measurement of single voxel-values, for example,
SUVmax. With regard to their use as early response indi-
cators in bevacizumab treatment, reports are conflicting.
Whereas studies using bevacizumab combined with cyto-
toxic treatment have shown their potential as early
response detectors [7–9], several authors have indicated a
noncorrespondence between vascular functional and
metabolic response in tumors undergoing bevacizumab
monotherapy [10].
With growing interest in measuring tumor heterogeneity,
investigators have discovered several 18F-FDG PET-
derived heterogeneity parameters as a potential alter-
native biomarker of response to treatment in different
cancers [11–15]. These heterogeneity parameters encode
additional spatial information as opposed to whole-tumor
derived metrics such as SUVmean, SUVmax, and Volmet,
which convey no information regarding spatial tumor
heterogeneity. Because of the known tumor hetero-
geneity in VEGF-A expression [16], it is logical to expect
differences in metabolic heterogeneity in treated tumors,
with regions of high VEGF-A expression responding to
bevacizumab differently from those with low VEGF-A
expression.
We hypothesized that 18F-FDG PET-derived para-
meters of spatial heterogeneity may be superior in
response assessment compared with whole-tumor-based
parameters such as morphologic tumor volume (Volmet),
maximum metabolism (Metmax), and mean metabolism
(Metmean). Hence the objective of this exploratory
case–control study was to identify potential new
18F-FDG PET biomarkers of early response assessment
by comparing 18F-FDG PET-derived texture parameters
with five conventional parameters, that is, morphologic
tumor volume (Volcal), change in morphologic tumor
volume (Δvol), Volmet, Metmax, and Metmean, in colorectal
xenograft models treated with bevacizumab.
Materials and methods
Animal studies were carried out in accordance with UK
Research Council’s and Medical Research Charities’
guidelines on responsibility in the use of animals in
bioscience research under a UK home office license.
Fourteen CD1/nu/nu athymic nude mice (Charles River,
Harlow, UK) were inoculated subcutaneously in the right
dorsal flank with poorly differentiated colon adenocarci-
noma cells (cell line LS174T; 5× 106 cells/mouse) [17].
The tumors were allowed to grow for 3 weeks until they
reached 6–9 mm diameter by caliper measurement. After
3 weeks, baseline tumor volumes (length×width2/2 [18])
were measured with calipers. Seven mice (treatment
group) were treated with bevacizumab (Avastin;
Genentech, San Francisco, California, USA) at a dose of
5 mg/kg through intraperitoneal injection on alternate
weekdays for six doses. The remaining seven mice were
left untreated as control group. After 2 weeks of
treatment, final volumes (Volcal) were calculated with
calipers in all mice to document tumor growth as percent
change in tumor volume: Δvol= 100× (final volume−
baseline volume)/baseline volume.
NanoPET/CT imaging of both groups of mice was per-
formed with a small animal Bioscan NanoPET/CT (Mediso,
Budapest, Hungary). For PET scanning, all mice were
anesthetized with inhalational isoflurane (induction isoflurane
4% at 0.8–1 l/min followed by isoflurane 2.5% by anesthetic
mask at 0.8 l/min) throughout the scanning with respiratory
monitoring and mouse bed temperature maintained at 30°C.
All mice received 5±0.2MBq of 18F-FDG PET by tail vein
followed by PET imaging acquired at 45–60min. Images
were reconstructed with the ordered subset expectation
maximization algorithm using NanoPET/CT scanner
embedded software using an energy window of 400–600 keV,
coincidence relation of 1–3, and isotropic voxel dimensions of
0.6mm. After decay correction, voxel uptake values were
converted to percentage injected dose per gram of tissue (%
ID/g) assuming a tissue density of 1 g/cm3. The reconstructed
images were then transferred in Digital Imaging and
Communications in Medicine format to MATLAB R2012b
(MathWorks Inc., Natick, Massachusetts, USA) for analysis.
Texture features were analyzed in 18F-FDG PET/CT
images using an in-house software implemented in
MATLAB (Release 2016b; The MathWorks Inc.).
The tumors were delineated with the fuzzy locally
adaptive Bayesian (FLAB) algorithm as follows: First, a
crude bounding volume was manually drawn encom-
passing the entire tumor and 1–3 mm of adjacent back-
ground region [19]. This bounding volume was subjected
to FLAB which classified all voxels into three classes:
tumor, background, and region of partial volume aver-
aging. The FLAB algorithm used to classify the voxels is
described in detail by Hatt et al. [19]. A final volume of
interest (VOI) was obtained by discarding voxels classi-
fied as background. The VOI was quantized into 64
equally sized bins. One hundred and fourteen computa-
tional features (15 geometric, six model-based, 37 first-
order, 21 second-order, and 35 higher-order texture fea-
tures) were derived from each VOI. Geometric features
describe tumor morphological features such as volume,
diameter, and surface-to-volume ratio. Model-based fea-
tures, that is, those derived from the fractal dimension of
the VOI, describe texture complexity at multiple scales.
First-order texture features such as maximum and mean
metabolism (i.e. highest activity voxel in the VOI),
skewness, and kurtosis are based on statistical histograms
and give no information on the spatial distribution of
voxels within the image. Second-order features are
derived from gray-level co-occurrence matrices and are
locoregional, providing information on pair-wise co-
occurrence of gray values in a given direction. Higher-
order locoregional texture features include gray-level run
length, gray-level size zone, and neighborhood gray tone
difference matrices. These take larger neighborhoods of
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similar gray values in different ways in three-dimension
[20–22].
Following imaging, all mice were sacrificed and their
tumors excised and analyzed as follows: First, pathologic
tumor specimens were stained for CD34 antibodies (a
marker of vascularity) using mouse monoclonal antibody
to CD34 with biotinylated rat anti-mouse immunoglo-
bulins (Vector Laboratories, Burlingame, California,
USA) [23]. An enhanced biotin/avidin immunoperox-
idase system, Vectastain ABC kit (Vector Laboratories)
and liquid 3,3′-diaminobenzidine+ chromogen (Dako,
Ely, Cambridgeshire, UK) were used to detect antibody
binding. Stained sections were viewed under a 10x
objective on a Leica DMRB light microscope with an
automated stage (Leica Microsystems Ltd, Milton
Keynes, UK). Images of whole-tumor sections were
captured and tiled using a QICAM FAST1394 color
camera (QImaging Corporation, Burnaby, Canada) and
Surveyor software (Objective Imaging Ltd, Cambridge,
UK) [23]. Image analysis was performed with the
operator (A.W.) blinded to mouse and treatment groups
in (ImageJ; NIH, Bethesda, Maryland, USA) to deter-
mine percentage area of the tumor section with positive
3,3′-diaminobenzidine staining. Microvessel density
(MVD) was determined by manually counting stained
vessels in ImageJ. Stained vessels were highlighted by
adjusting the color threshold (hue, saturation, and
brightness) and the image was overlaid with a
1000× 1000 pixel grid to aid counting.
Statistical analysis
Continuous variables were reported as mean ± SD. The
Shapiro–Wilk test was used to determine which variables
were normally distributed. For normally distributed
variables, differences of means were compared between
treated and control mice using the Welch-corrected two-
sample t-test, whereas for non-normally distributed vari-
ables, the differences of medians were compared using
the Wilcoxon signed-rank test.
Pathological response to bevacizumab treatment was
confirmed by comparing mean MVD of treated versus
control mice. To determine whether there was any
tumor-growth delay in treated versus control mice, Δvol
were compared as the difference of medians between
treated and control mice. Likewise, medians of Volmet
and Metmean determined from
18F-FDG PET imaging
were also compared between the treated and control
mice to determine the role of conventional 18F-FDG
PET in differentiating the two groups.
Finally, 18F-FDG PET-derived texture variables were
compared between treated and untreated mice. The
starting variable-set of 114 variables was reduced by
excluding highly correlated variables using ‘caret’ pack-
age of R version 3.3.1 (The R Foundation, Vienna,
Austria), using 0.8 as the cutoff for pair-wise absolute
correlation [24]. The remaining variables were compared
between treated and control mice for difference of means
(or medians as appropriate). Bonferroni correction was
applied to the P values to mitigate false positives arising
from multiple testing using a P value of 0.002.
Differences between the two groups were summarized in
a table and illustrated by bar plots. The length of each bar
would indicate fold change in a variable with respect to
the control group. Fold change was computed using the
formula: (value in the treated group− value in the control
group)/value in control group. For example, a fold change
of 0 would indicate no change, + 1 would indicate that
the mean value in the treatment group was twice that of
control, and − 1 would indicate that the mean value for
the treatment group was half that of the control group.
Results
Treated tumors showed a lower number of CD34 posi-
tive vessels per unit area than control tumors, that is,
2.91× 10− 6 versus 6.57× 10− 6 (P= 0.032) confirming
pharmacologically effective administration of bev-
acizumab. Measured directly with calipers, treated and
control mice had mean Volcal of 312 ± 72.93 mm3 and
352 ± 47.5 mm3, respectively (P= 0.7). There were no
significant growth delays from bevacizumab treatment of
treated mice, with both groups showing similar mean Δvol
of 424.53 ± 238.7% (treated) versus 434.8 ± 117.9% (con-
trol, P= 0.9; Fig. 1).
Conventional imaging metrics response
Standard methods of response assessment with 18F-FDG
PET showed no differences between treated and control
mice: treated and control mice showed similar median
Volmet of 375 ± 96.9 versus 384.9 ± 60.2 mm3 (P= 0.28),
Metmax of 43.14 ± 15.3 versus 47.6 ± 25.7%ID/g (P= 0.7),
and Metmean of 14.22 ± 5.32 versus 17.85 ± 7.5%ID/g
(P= 0.32; Fig. 1).
18F-FDG PET-derived texture parameter response
After excluding highly correlated texture parameters, 24
texture features remained. These were six first-order, four
second-order, seven high-order statistical features, five
geometric, and two model-based features (Table 1). Four
variables were statistically significantly different between
the two groups, that is, surface area to volume ratio
(P= 0.004), fractal dimension maximum (FDmax; P= 0.03),
gray-level run-length short-run emphasis (GLRL-SRE;
P= 0.02), and gray-level size-zone matrix size zone varia-
bility (GLSZM-SZV; P= 0.001). After applying the
Bonferroni-adjusted P value cutoff (P< 0.002), one variable
remained (GLSZM-SZV; P= 0.001). Treated mice showed
GLSZM-SZV that was on average − 0.74-fold (or 26%) that
of control mice. Figure 2 provides a graphical summary of
fold change (with respect to control group) in each of the 24
texture variables.
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Discussion
In our study, we assessed conventional response biomarkers
and a number of texture parameters in a mouse xenograft
colorectal cancer model treated with antiangiogenic targeted
agent bevacizumab. Our study was based on the premise
that tumors treated with bevacizumab do not undergo
changes in size early because of the cytostatic rather than
cytoreductive effect of bevacizumab; however, we hypo-
thesized that there may be changes within the tumor
microenvironment secondary to the vascular remodeling
following bevacizumab treatment that may be detectable
and quantifiable by 18F-FDG PET texture analysis. We
found that after 2 weeks of bevacizumab treatment, four
18F-FDG PET-derived texture parameters, that is, surface-
to-volume ratio, FDmax, GLSZM-SZV, and GLRL-SRE,
were significantly different between treated and control
mice. After applying Bonferroni correction for multiple
comparisons, a single parameter, GLSZM-SZV (−0.74-fold
difference; P=0.001), remained significant. In contrast,
conventional descriptors of tumor response, that is, mor-
phologic tumor volumes and metabolism (Metmax and
Metmean), were not significantly different between the two
groups of mice.
The GLSZM provides an estimation of a bivariate con-
ditional probability density function of image distribution
values [25]. The more homogeneous the texture, the
wider and flatter the matrix. High GLSZM-SZV is an
indicator of inhomogeneity; for any given gray-level
intensity, there are numerous patches of different sizes.
In our study, treated mice had much smaller values of
GLSZM-SZV compared with control mice, which can be
interpreted as their 18F-FDG PET images showing little
variation in sizes of isometabolic patches. Although,
GLSZM-SZV by itself does not allow interpretation of
the sizes of patches, the patch sizes can be inferred to be
generally smaller in treated mice, based on their gen-
erally higher GLRL-SRE (0.38-fold difference; P= 0.02)
and FDmax (0.22-fold difference; P= 0.03), even though
Fig. 1
Comparing treated and control mice in terms of differences in MVD (a), volumes (caliper-measured) (b), and temporal change in volume of tumors in
treated mice (c) and control mice (d). In (a) and (b), the heights of the bars denote mean values of tested variables and whiskers, the SEM. As shown
in (a), there were significant differences in MVD between treated and control mice, confirming pathologic response to bevacizumab in treated mice.
However, final tumor volumes of (b) and Δvol of treated and untreated mice (c and d, respectively) were not significantly different. MVD, microvessel
density.
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both variables were excluded after applying the
Bonferroni-adjusted P value cutoff of 0.002. GLRLs
compute contiguous sequences of voxels displaying
similar gray levels in given directions. A high GLRL-
SRE value indicates a finely textured image dominated
by short runs of voxel gray levels [26]. Likewise, a high
FDmax value corresponds to a high frequency of variation
in voxel gray levels, that is, a fine texture [27,28]. Finally,
we found a surface-to-volume ratio to be significantly
lower in the treatment group (− 0.12-fold difference;
P= 0.004). This finding suggests that treated tumors
became more compact and approached a spheroidal, as
opposed to irregular, shape. Looking at these combina-
tions of geometric and texture variables, it appears that
18F-FDG activity in treated tumors was more compact
and exhibited finer variation spatially, whereas untreated
tumors were more irregular and exhibited a coarser
metabolic texture.
There are only a few reports investigating the metabolic
and functional effects of early bevacizumab treatment as
monotherapy. These studies are generally in agreement
with ours. Willett et al. [2] monitored six patients with
rectal cancer on treatment with bevacizumab. After
12 days of bevacizumab treatment, the authors found that
only one of five patients experienced tumor regression
and another one patient experienced a decrease in tumor
18FDG uptake, the rest showing stable tumor sizes and
metabolic activity respectively. In contrast, tumor per-
fusion decreased by 40–45% and blood volume by
16–39% in most patients. The authors did not test spatial
metabolic texture indices as response biomarkers, how-
ever. Our findings based on caliper and 18F-FDG PET
measurements of tumor volumes and Metmax, as well as
Metmean, are in concordance with the results reported
by Willet and colleagues. Kim et al. [3] measured CT-
derived flow parameters and 18F-FDG PET-derived
SUVmax, SUVmean, total lesion glycolysis, gray-level co-
occurrence matrix (GLCM) entropy, and GLCM homo-
geneity in a case–control rabbit VX2 tumor model (used
to model hepatocellular carcinoma) [29]. Serial imaging
performed up to 14 days following treatment with bev-
acizumab did not show any significant differences
between the two groups of rabbits in any of the 18F-FDG
PET-derived metrics, whereas CT-derived blood flow
and blood volume were different. In our study, we also
did not find significant differences in Metmax, Metmean, or
first-order entropy, although we found GLSZM-SZV to
be significantly different between the two groups – not
tested by Kim and colleagues. We believe that GLCM-
derived features extract different textural information
Table 1 Summary differences in mean texture parameters between treated and control mice
Texture parameters Mean (treated) Mean (control) Fold change P value (test used)
Geometric
Surface area: volume (mm−1)* 121.85 138.17 −0.12 0.004a
Eccentricity 0.7 0.64 0.09 0.3b
Compactness 0.008 0.0078 0.02 0.81b
Solidity 0.837 0.832 0.01 0.46a
Spikiness 13.71 15.15 −0.09 0.47b
Model
FD-STD 0.23 0.228 0.01 0.92b
FDmax* 4.28 3.52 0.22 0.03
b
First-order
First-order entropy 4.24 4.29 −0.01 0.8a
Coefficient of variation 0.442 0.436 0.014 0.9b
Kurtosis 3.85 3.09 0.24 0.38a
Skewness 0.66 0.6 0.1 0.79b
Metabolism (min) (%ID/g) 2.0 3.48 −0.42 0.24b
Total lesion metabolism ( mm3%ID/g) 4.76 7.11 −0.33 0.01b
Second-order
GLCM CP 6.2×105 4.9×105 0.26 0.53b
GLCM CS 4.9×103 4.5×103 0.09 0.87b
GLCM IMC 0.86 0.87 −0.007 0.85b
GLCM max probability 0.013 0.01 0.26 0.32a
Higher-order
GLSZM size zone variability† 475.47 1822.52 −0.74 0.001a
GLSZM LZHIE 9.3×105 2.9×105 2.23 0.21a
GLSZM LIZE 0.56 0.54 0.03 0.21b
GLSZM zone percentage 0.16 0.17 −0.07 0.76b
GLRL long run HGLE 1123.89 914.58 0.23 0.34b
GLRL short-run HGLE 3.42 2.44 0.4 0.9a
GLRL-SRE* 0.07 0.05 0.38 0.02a
FD, fractal dimension; FD-STD, FD-standard deviation; GLCM, gray-level co-occurrence matrix; GLCM CP, GLCM cluster prominence; GLCM CS, GLCM cluster shade;
GLCM IMC, GLCM information measure correlation; GLRL, gray-level run-length; GLRL long run HGLE, GLRL long run high gray-level run emphasis; GLRL-SRE, GLRL
short-run emphasis; GLSZM, gray-level size-zone matrix; GLSZM LIZE, GLSZM low-intensity zone emphasis; GLSZM LZHIE, GLSZM long zone high-intensity emphasis.
aWilcoxon signed-rank sum test.
bt-Test.
*P<0.05 (unadjusted).
†P<0.002 (Bonferroni-adjusted).
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compared with GLSZM-derived features, as indicated by
the absence of correlation between GLCM-derived and
GLSZM-derived features in our study – GLCM entropy
was found to be correlated with first-order entropy
(r= 0.87; P=0.001) and hence only first-order entropy
was retained for further analysis.
A potential limitation of this study is that our sample size of
14 mice was relatively small, as is typical of xenograft studies
[30], and it is possible that further texture features could
have shown statistical significance with a larger cohort.
Furthermore, our findings only reflect changes in tumor
metabolism in response to bevacizumab, whereas, in typical
clinical scenarios, bevacizumab is given in combination with
chemotherapy. Nonetheless, we believe that quantification
of tumor size and metabolic effects of bevacizumab mono-
therapy are useful to enable elucidation of its relative con-
tribution (or lack thereof) in different scenarios of
combination treatments.
Conclusion
The findings from this exploratory study suggest that early
during treatment with bevacizumab, responding tumors may
undergo metabolic changes in the microenvironment
manifesting as a transition from coarse to fine texture of
18F-FDG distribution and from an irregular to a more com-
pact shape. In contrast, tumor sizes and maximum (or mean)
metabolism do not change significantly during early bev-
acizumab treatment and are not reliable biomarkers of early
response. These preliminary findings will need prospective
evaluation in human studies, but offer novel biomarkers of
treatment response to bevacizumab treatment that may be
more accurate than conventional size or metabolic activity
parameters.
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Fig. 2
Bar plots illustrating differences in median values of individual texture parameters left after excluding highly correlated features. Four subplots are
generated after grouping texture features together. Bars pointing toward the left indicate that corresponding texture features were lower in the
treatment group versus the control group. Statistically, significant differences are indicated in blue. FD, fractal dimension; FD-STD, FD-standard
deviation; GLCM, gray-level co-occurrence matrix; GLCM CP, GLCM cluster prominence; GLCM CS, GLCM cluster shade; GLCM IMC, GLCM
information measure correlation; GLRL, gray-level run-length; GLRL long run HGLE, GLRL long run high gray-level run emphasis; GLRL-SRE, GLRL
short-run emphasis; GLSZM, gray-level size zone matrix; GLSZM LIZE, GLSZM low-intensity zone emphasis; GLSZM LZHIE, GLSZM long zone
high-intensity emphasis.
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